Sanofi (SNY) EBITDA Margin (2009 - 2026)

Sanofi (SNY) posted EBITDA Margin of 120.56% for Q2 2026, up 4.02% sequentially from 115.9% in Q1 2026, and up 113.0% YoY from 56.6% in Q2 2025.

Sanofi (SNY) EBITDA Margin (2009 - 2026) Analysis & Trends

Sanofi has reported EBITDA Margin for 18 years, with the latest figure at 120.56% in Q2 2026.

Quarterly EBITDA Margin rose 113.0% year-over-year to 120.56% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 161.46% (up 896.0% YoY) and the FY2025 annual result came in at 14.54%, down 311.0% from the prior year.
EBITDA Margin rose to 120.56% in Q2 2026 per SNY's latest filing, from 115.9% in the prior quarter.
Over five years, EBITDA Margin peaked at 340.95% in Q4 2024 and troughed at 120.82% in Q4 2025.
A 5-year average of 115.43% and a median of 116.76% in 2023 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2024 and 2025: EBITDA Margin jumped 22347 bps in 2024, then slumped 46178 bps in 2025.
Over 5 years, EBITDA Margin stood at 121.92% in 2022, then fell by 4 bps to 117.49% in 2023, then surged by 190 bps to 340.95% in 2024, then slumped by 135 bps to 120.82% in 2025, then jumped by 200 bps to 120.56% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 120.56%, 115.9%, and 120.82% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	28.21%
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	37.86%
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-3.52%
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	32.97%
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	20.57%
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	34.95%
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	-133.21%
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	28.37%
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	5.72%
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	124.39%

Download Data